TRVI
Trevi Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.68B
P/E Ratio
—
EPS
$-0.32
Beta
1.00
52W High
$14.39
52W Low
$5.12
50-Day MA
$11.28
200-Day MA
$9.92
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious neurology-mediated conditions. The company is headquartered in New Haven, Connecticut.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-49.18M |
| Operating Margin | 0.00% |
| Return on Equity | -30.20% |
| Return on Assets | -20.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.43 |
| Price-to-Book | 8.36 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -4.92 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $128.40M |
| Float | $103.93M |
| % Insiders | 0.68% |
| % Institutions | 103.92% |
Historical Volatility
HV 10-Day
65.17%
HV 20-Day
58.87%
HV 30-Day
66.22%
HV 60-Day
62.97%
HV Rank
72.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($21.55 target)
2
Strong Buy9
BuyData last updated: 4/9/2026